1. Home
  2. PRPO vs ENG Comparison

PRPO vs ENG Comparison

Compare PRPO & ENG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRPO
  • ENG
  • Stock Information
  • Founded
  • PRPO N/A
  • ENG 1985
  • Country
  • PRPO United States
  • ENG United States
  • Employees
  • PRPO 57
  • ENG N/A
  • Industry
  • PRPO Biotechnology: Laboratory Analytical Instruments
  • ENG Military/Government/Technical
  • Sector
  • PRPO Industrials
  • ENG Consumer Discretionary
  • Exchange
  • PRPO Nasdaq
  • ENG Nasdaq
  • Market Cap
  • PRPO 9.5M
  • ENG 6.7M
  • IPO Year
  • PRPO N/A
  • ENG 1998
  • Fundamental
  • Price
  • PRPO $6.59
  • ENG $1.37
  • Analyst Decision
  • PRPO
  • ENG
  • Analyst Count
  • PRPO 0
  • ENG 0
  • Target Price
  • PRPO N/A
  • ENG N/A
  • AVG Volume (30 Days)
  • PRPO 7.9K
  • ENG 16.8K
  • Earning Date
  • PRPO 11-11-2024
  • ENG 11-11-2024
  • Dividend Yield
  • PRPO N/A
  • ENG N/A
  • EPS Growth
  • PRPO N/A
  • ENG N/A
  • EPS
  • PRPO N/A
  • ENG N/A
  • Revenue
  • PRPO $16,719,999.00
  • ENG $28,773,000.00
  • Revenue This Year
  • PRPO $75.18
  • ENG $694.29
  • Revenue Next Year
  • PRPO N/A
  • ENG N/A
  • P/E Ratio
  • PRPO N/A
  • ENG N/A
  • Revenue Growth
  • PRPO 52.61
  • ENG N/A
  • 52 Week Low
  • PRPO $4.31
  • ENG $1.01
  • 52 Week High
  • PRPO $8.99
  • ENG $2.80
  • Technical
  • Relative Strength Index (RSI)
  • PRPO 52.82
  • ENG 51.47
  • Support Level
  • PRPO $6.42
  • ENG $1.26
  • Resistance Level
  • PRPO $6.99
  • ENG $1.36
  • Average True Range (ATR)
  • PRPO 0.33
  • ENG 0.09
  • MACD
  • PRPO -0.04
  • ENG 0.00
  • Stochastic Oscillator
  • PRPO 69.91
  • ENG 49.00

About PRPO Precipio Inc.

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

About ENG ENGlobal Corporation

ENGlobal Corp engages in providing engineering and professional services to the energy industry. The company operates through two segments Commercial and Government Services. The Commercial segment derives revenue on contracts from time-and-material fees charged for professional and technical services. The Government segment provides services related to the design, integration and implementation of process distributed control and analyzer systems, advanced automated data gathering systems, information technology and the maintenance of these systems to the U.S. Government globally.

Share on Social Networks: